Valion Bio, Inc. Common Stock

VBIOStock
$0.53
Market Cap$1.71M
P/E
Div yield
Beta3.47

Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-39.54%
VGM Score44.22
Market Capitalization$1.71M

Industry Peers — Electromedical Equipment(32)

About

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.